333 related articles for article (PubMed ID: 17186528)
1. Cumulative cost pattern comparison of prostate cancer treatments.
Wilson LS; Tesoro R; Elkin EP; Sadetsky N; Broering JM; Latini DM; DuChane J; Mody RR; Carroll PR
Cancer; 2007 Feb; 109(3):518-27. PubMed ID: 17186528
[TBL] [Abstract][Full Text] [Related]
2. The changing costs of radiation treatment for early prostate cancer in Ontario: a comparison between conventional and conformal external beam radiotherapy.
Poon I; Pintilie M; Potvin M; McGowan T
Can J Urol; 2004 Feb; 11(1):2125-32. PubMed ID: 15003151
[TBL] [Abstract][Full Text] [Related]
3. The economic burden of prostate cancer, California, 1998.
Max W; Rice DP; Sung HY; Michel M; Breuer W; Zhang X
Cancer; 2002 Jun; 94(11):2906-13. PubMed ID: 12115378
[TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer.
Crawford ED; Black L; Eaddy M; Kruep EJ
Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):162-7. PubMed ID: 20125121
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer--prevalence-based healthcare costs.
Norlund A; Alvegård T; Lithman T; Merlo J; Noreen D
Scand J Urol Nephrol; 2003; 37(5):371-5. PubMed ID: 14594683
[TBL] [Abstract][Full Text] [Related]
6. Adenocarcinoma of the prostate: an expensive way to die.
Piper NY; Kusada L; Lance R; Foley J; Moul J; Seay T
Prostate Cancer Prostatic Dis; 2002; 5(2):164-6. PubMed ID: 12497008
[TBL] [Abstract][Full Text] [Related]
7. Technological changes in the management of prostate cancer result in increased healthcare costs--a retrospective study in a defined Swedish population.
Sennfält K; Carlsson P; Thorfinn J; Frisk J; Henriksson M; Varenhorst E
Scand J Urol Nephrol; 2003; 37(3):226-31. PubMed ID: 12775282
[TBL] [Abstract][Full Text] [Related]
8. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.
Grover SA; Coupal L; Zowall H; Rajan R; Trachtenberg J; Elhilali M; Chetner M; Goldenberg L
CMAJ; 2000 Apr; 162(7):977-83. PubMed ID: 10763395
[TBL] [Abstract][Full Text] [Related]
9. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
[TBL] [Abstract][Full Text] [Related]
10. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.
Elliott SP; Meng MV; Elkin EP; McAninch JW; Duchane J; Carroll PR;
J Urol; 2007 Aug; 178(2):529-34; discussion 534. PubMed ID: 17570425
[TBL] [Abstract][Full Text] [Related]
11. A nationwide charge comparison of the principal treatments for early stage prostate carcinoma.
Brandeis J; Pashos CL; Henning JM; Litwin MS
Cancer; 2000 Oct; 89(8):1792-9. PubMed ID: 11042575
[TBL] [Abstract][Full Text] [Related]
12. Predictors of patient reported outcomes and cost of care in younger men with newly diagnosed prostate cancer.
Jayadevappa R; Chhatre S; Wein AJ; Malkowicz SB
Prostate; 2009 Jul; 69(10):1067-76. PubMed ID: 19343738
[TBL] [Abstract][Full Text] [Related]
13. Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor.
Sadetsky N; Lubeck DP; Pasta DJ; Latini DM; DuChane J; Carroll PR
BJU Int; 2008 Mar; 101(6):691-7. PubMed ID: 18291018
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database.
Sadetsky N; Elkin EP; Latini DM; DuChane J; Carroll PR;
Prostate Cancer Prostatic Dis; 2008; 11(3):280-7. PubMed ID: 17893700
[TBL] [Abstract][Full Text] [Related]
15. Health related quality of life and direct medical care cost in newly diagnosed younger men with prostate cancer.
Jayadevappa R; Bloom BS; Chhatre S; Fomberstein KM; Wein AJ; Malkowicz SB
J Urol; 2005 Sep; 174(3):1059-64; discussion 1064. PubMed ID: 16094058
[TBL] [Abstract][Full Text] [Related]
16. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy.
Malmberg I; Persson U; Ask A; Tennvall J; Abrahamsson PA
Urology; 1997 Nov; 50(5):747-53. PubMed ID: 9372886
[TBL] [Abstract][Full Text] [Related]
17. Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK.
Fourcade RO; Benedict A; Black LK; Stokes ME; Alcaraz A; Castro R
BJU Int; 2010 Jan; 105(1):49-56. PubMed ID: 20132102
[TBL] [Abstract][Full Text] [Related]
18. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data.
Lamerato L; Havstad S; Gandhi S; Jones D; Nathanson D
Cancer; 2006 May; 106(9):1875-82. PubMed ID: 16572409
[TBL] [Abstract][Full Text] [Related]
19. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
Alexandrescu DT
Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
[TBL] [Abstract][Full Text] [Related]
20. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
